公开(公告)号：US20240091175A1

公开(公告)日：2024-03-21

申请号：US18370633

申请日：2023-09-20

申请人： UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

发明人： Matthew Nystoriak ,  Aruni Bhatnagar

IPC分类号： A61K31/137 ,  A61P9/08

CPC分类号： A61K31/137 ,  A61P9/08

摘要： In certain embodiments, the present invention provides a method of modulating myocardial blood flow (MBF) as compared to a control in a patient in need thereof, comprising administering an agent that interacts with a Kvβ protein.

公开(公告)号：US20240066495A1

公开(公告)日：2024-02-29

申请号：US18472316

申请日：2023-09-22

申请人： Origin Life Sciences, Inc.

发明人： Michael PARIS ,  Kirill GUTSOL ,  Howard NELSON ,  David MECK ,  Lindley CURAMENG ,  Andre' DiMINO

IPC分类号： B01J19/08 ,  A61K33/00 ,  A61P9/08 ,  C01B21/24 ,  C01B21/32

CPC分类号： B01J19/088 ,  A61K33/00 ,  A61P9/08 ,  C01B21/24 ,  C01B21/32 ,  A61M13/003 ,  B01J2219/0871

摘要： A device and method for forming NO-containing gas flow to treat a biological object is disclosed. The device may include an anode, a cathode, an interelectrode area between the cathode and the anode, an NO-containing gas flow outlet channel leading from the interelectrode area to a nozzle for directing and releasing the NO-containing gas flow from the device and a mechanism to adjust a relative position between the anode and the cathode to produce varying concentrations of NO. In addition, the device may include one or more features for interconnecting the various components to ensure proper and consistent assembly of the device.

公开(公告)号：US20230149336A1

公开(公告)日：2023-05-18

申请号：US17907645

申请日：2021-03-24

申请人： Evonik Operations GmbH

发明人： Rosario LIZIO ,  Michael SCHWARM ,  Albino CARRIZZO ,  Carmine VECCHIONE

IPC分类号： A61K31/202 ,  A23L33/00 ,  A23L33/12 ,  A23L33/105 ,  A61K31/198 ,  A61P9/08 ,  A61P39/06 ,  A61K31/7048 ,  A61K36/185 ,  A61K36/45

CPC分类号： A61K31/202 ,  A23L33/40 ,  A23L33/12 ,  A23L33/105 ,  A61K31/198 ,  A61P9/08 ,  A61P39/06 ,  A61K31/7048 ,  A61K36/185 ,  A61K36/45

摘要： A composition for use as antioxidant, where the composition has at least one polyunsaturated fatty acid component and at least one anthocyanin component. The polyunsaturated fatty acid component is an amino acid salt of the omega-3 fatty acids eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA). The anthocyanin component is cyanidin-3-glucoside, delphinidin-3-glucoside, malvidin-3-galactoside, peonidin-3-galactoside, or malvidin-3-glucoside. A method for treating a disease with the composition. A method of providing an antioxidant to a subject with the composition.

公开(公告)号：US11938185B2

公开(公告)日：2024-03-26

申请号：US17122243

申请日：2020-12-15

申请人： H. LUNDBECK A/S

发明人： Maria-Cristina Loomis ,  Leon F. Garcia-Martinez ,  Benjamin H. Dutzar ,  Daniel S. Allison ,  Katherine Lee Hendrix ,  Ethan W. Ojala ,  Pei Fan ,  Jeffrey T. L. Smith ,  John A. Latham ,  Charlie Karasek ,  Jenny Mulligan ,  Michelle Scalley-Kim ,  Erica Stewart ,  Vanessa Lisbeth Rubin ,  Jens J. Billgren

IPC分类号： A61K39/395 ,  A61P9/08 ,  A61P25/06 ,  C07K14/705 ,  C07K14/72 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/42 ,  C12N5/07 ,  C12N15/09 ,  C12N15/63 ,  G01N33/68 ,  A61K38/00 ,  A61K38/17 ,  A61K38/22 ,  A61K39/00 ,  A61K48/00 ,  C07K14/47 ,  C07K14/575

CPC分类号： A61K39/3955 ,  A61P9/08 ,  A61P25/06 ,  C07K14/70503 ,  C07K14/72 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/2869 ,  C07K16/4241 ,  C12N5/06 ,  C12N15/09 ,  C12N15/63 ,  G01N33/6854 ,  A61K38/00 ,  A61K38/17 ,  A61K38/22 ,  A61K2039/505 ,  A61K48/00 ,  C07K14/47 ,  C07K14/575 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/575 ,  Y02A50/30

摘要： The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

公开(公告)号：US20180273480A1

公开(公告)日：2018-09-27

申请号：US15762849

申请日：2016-09-21

申请人： WEIFANG SHENGYU PHARMA CO., LTD.

发明人： Liwei ZHU ,  Xuefeng MEI ,  Jianrong WANG

IPC分类号： C07D213/80 ,  B01D9/00

CPC分类号： C07D213/80 ,  A61K31/455 ,  A61P9/08 ,  B01D9/0031 ,  B01D9/0054 ,  B01D9/0063 ,  C07D213/803

摘要： Provided are an inositol nicotinate crystalline form A and a preparation method therefor. The X-ray powder diffraction analysis, obtained by using Cu-Kα ray measurement, of the inositol nicotinate crystalline form A has obvious characteristic diffraction peaks at least at 2θ values, expressed in degrees, of 7.05, 7.41, 9.74, 17.80, 19.86, 23.57, 25.48 and 26.20 with an error range of +/−0.2°. The preparation method is one of or a mixed crystallization method of two or more of an evaporation crystallization method, a cooling crystallization method or an anti-solvent crystallization method. The process thereof is simple and easy to operate, and has more selectivity; the inositol nicotinate crystalline form A can be prepared by various methods, and the prepared product has a good crystallization degree and high chemical stability; and the inositol nicotinate crystalline form A prepared by the present method does not have the problem that a residual solvent is out-of-limit.

公开(公告)号：US20180147208A1

公开(公告)日：2018-05-31

申请号：US15575978

申请日：2016-05-23

申请人： Merck Sharp & Dohme Corp.

发明人： Joie GARFUNKLE ,  Olga ORNOSKI ,  Dann L. PARKER, JR. ,  Subharekha RAGHAVAN ,  Libo XU

IPC分类号： A61K31/519 ,  C07D519/00 ,  A61P9/08 ,  A61K45/06

CPC分类号： A61K31/519 ,  A61K45/06 ,  A61P9/08 ,  C07D519/00

摘要： A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or pharmaceutically acceptable salt thereofs, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or pharmaceutically acceptable salts thereof.

公开(公告)号：US09982046B2

公开(公告)日：2018-05-29

申请号：US15346026

申请日：2016-11-08

申请人： NOVARTIS AG

发明人： Kurt Alex Heldwein ,  Igor Splawski ,  Jennifer Brogdon ,  Joshua Goldstein ,  William Dole ,  John Trauger ,  Chonghui Zhang

IPC分类号： A61P9/08 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61K39/395 ,  C07K16/28 ,  A61K9/00 ,  A61K45/06 ,  C07K14/47 ,  A61K39/00

CPC分类号： C07K16/28 ,  A61K9/0019 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61P9/04 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  C07K14/4726 ,  C07K16/2851 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20170260272A1

公开(公告)日：2017-09-14

申请号：US15390067

申请日：2016-12-23

申请人： Kurt Alex HELDWEIN ,  Jennifer BROGDON ,  William DOLE ,  John TRAUGER ,  Yuting TANG ,  Julia NEUGEBAUER ,  Annika SCHMID

发明人： Kurt Alex HELDWEIN ,  Jennifer BROGDON ,  William DOLE ,  John TRAUGER ,  Yuting TANG ,  Julia NEUGEBAUER ,  Annika SCHMID

IPC分类号： C07K16/28

CPC分类号： C07K16/2851 ,  A61K39/3955 ,  A61K2039/505 ,  A61P9/04 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  C07K14/33 ,  C07K14/4726 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20170020899A1

公开(公告)日：2017-01-26

申请号：US15124804

申请日：2015-03-13

申请人： MADELEINE PHARMACEUTICALS PTY LTD

发明人： Thomas Robert GEIMER

IPC分类号： A61K31/635 ,  A61K31/585 ,  A61K45/06 ,  A61K31/197 ,  A61K38/22

CPC分类号： A61K31/635 ,  A61K31/197 ,  A61K31/341 ,  A61K31/585 ,  A61K38/2221 ,  A61K38/2242 ,  A61K45/06 ,  A61P9/08 ,  A61P13/12 ,  C07K14/58 ,  A61K2300/00

摘要： A therapeutic method for treating and/or preventing diseases and medical conditions typically treated by administering diuretic agents (eg congestive heart failure). The method may comprise, for example, administering to a subject a diuretic agent in combination with vessel dilator (VSDL) or a variant or modified peptide thereof. The administration of the diuretic agent may be a component of a standard of care (SOC) treatment.

摘要翻译： 用于治疗和/或预防通常通过施用利尿剂（例如充血性心力衰竭）治疗的疾病和医学病症的治疗方法。 该方法可以包括例如向受试者施用与血管扩张剂（VSDL）或其变体或修饰的肽组合的利尿剂。 利尿剂的施用可以是护理标准（SOC）治疗的组分。

公开(公告)号：US20150004168A1

公开(公告)日：2015-01-01

申请号：US14307515

申请日：2014-06-18

申请人： Kurt Alex HELDWEIN ,  Igor SPLAWSKI ,  Jennifer BROGDON ,  Joshua GOLDSTEIN ,  William DOLE ,  John TRAUGER ,  Chonghui ZHANG

发明人： Kurt Alex HELDWEIN ,  Igor SPLAWSKI ,  Jennifer BROGDON ,  Joshua GOLDSTEIN ,  William DOLE ,  John TRAUGER ,  Chonghui ZHANG

IPC分类号： C07K16/28

CPC分类号： C07K16/28 ,  A61K9/0019 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61P9/04 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  C07K14/4726 ,  C07K16/2851 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

摘要翻译： 本发明涉及与人凝集素样氧化的低密度脂蛋白（LDL）（低密度脂蛋白）受体1（以下有时称为“LOX-1”）结合的单克隆抗体，以及包含该受体的药物组合物和治疗方法。